Sarbajit Mukherjee, MD, MS Sarbajit Mukherjee, MD, MS

Sarbajit Mukherjee

Medical Oncology

Specializing In:

Esophageal Cancer Gastric Cancer Neuroendocrine Tumors Colon Cancer

Special Interests:

Use of immune checkpoint inhibitors in solid tumors

About Sarbajit Mukherjee


Oncology is one of the most academic disciplines of medicine, and its scientific concepts are rapidly evolving. Over the past few years, a convergence of innovations has created an unprecedented opportunity for us to make a big impact on cancer. Working at a top-notch institution like Roswell Park Comprehensive Cancer Center allows me to integrate those cutting age innovations into the day-to-day care of my patients. I hope to see a day when cancer, stripped of its intimidation, will be "a word, not a sentence."


Roswell Park Comprehensive Cancer
  • Assistant Professor of Oncology
  • Department of Medicine
  • Member, Tumor Immunology and Immunotherapy Program
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
  • Clinical Assistant Professor


Education and Training:

  • 2010 - MD - Nilratan Sircar Medical College, West Bengal University of Health Sciences, India
  • 2018 - MS - Master of Science in Clinical and Translational Science, University of Oklahoma, Oklahoma City, OK


  • 2012-2015 - Saint Joseph Hospital, Chicago, IL


  • 2015-2018 - University of Oklahoma Health Sciences Center, Oklahoma City, OK

Board Certification:

  • 2018 - Medical Oncology - American Board of Internal Medicine
  • 2018 - Hematology - American Board of Internal Medicine
  • 2015 - Internal Medicine - American Board of Internal Medicine

Professional Memberships:

  • Society for Immunotherapy of Cancer
  • American Association for Cancer Research
  • American College of Gastroenterology
  • North American Neuroendocrine Tumor Society
  • European Society of Medical Oncology
  • American Society of Clinical Oncology

Professional Experience:

  • 2018-present - Board of Directors, Esophageal Cancer Action Network
  • 2017-2018 - Chief fellow, Hematology-Oncology, University of Oklahoma
  • 2017-2018 - Clinical Practice Guidelines Committee, ASCO
  • 2016-2018 - Professional Development Committee, ASCO

Honors & Awards:

  • Clinical Investigator Scholarship Award, North American Neuroendocrine Tumor Society
  • ASCO/AACR Methods in Clinical Cancer Workshop, Vail, CO
  • James N. George award for the outstanding fellow in hematology-oncology, University of Oklahoma
  • Gold Humanism Honor Society
  • Conquer Cancer Foundation Merit Award, ASCO
  • Alpha Omega Alpha (AOA) Honor Medical Society

Clinical Trials


Full Publications list on PubMed

Mukherjee S, Fountzilas C, Boland PM, Gosain R, Attwood K, Tan W, Khushalani N, Iyer R. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Target Oncol. 2019 Dec 4. PubMed PMID: 31802410.

Malhotra U*, Mukherjee S*, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani NI. Pralatrexate in combination with oxaliplatin in advanced esophago-gastric cancer: a phase II trial with predictive molecular correlates. Mol Cancer Ther. 2020 Jan;19(1):304-311.PubMed PMID: 31575653. *co-first author

Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer. 2019 Nov 12. PubMed PMID: 31714595.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 Jan; 25(1):141-151. PubMed PMID: 30420753.

Mukherjee S, Ibrahimi S, Khalid B, Roman D, Zhao D, Aljumaily R. Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study. J Oncol Pharm Pract. 2018 Jan 1:1078155218771152. PubMed PMID: 29690815.

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment